Semaglutide Causes Significant Fat Loss but Also Reduces Lean Muscle Mass
The SEMALEAN study found semaglutide 2.4mg produced substantial fat loss in obesity patients, but also significant lean mass reduction, with preserved handgrip strength at 12 months.
Quick Facts
What This Study Found
Semaglutide 2.4mg produced significant weight and fat loss but also reduced lean body mass, while handgrip strength was generally preserved through 12 months.
Key Numbers
How They Did This
Prospective observational study with 115 patients; body composition measured by DXA, muscle function by handgrip strength, and resting energy expenditure tracked at baseline, 7 months, and 12 months.
Why This Research Matters
The lean mass loss debate is one of the biggest concerns with GLP-1 medications. This study provides objective DXA-measured data showing the actual body composition changes during semaglutide treatment.
The Bigger Picture
As millions use GLP-1 medications for weight loss, understanding the ratio of fat-to-lean mass loss is critical for long-term health, especially in older adults at risk for sarcopenia.
What This Study Doesn't Tell Us
No control group; prospective but observational design; handgrip strength is a limited measure of overall muscle function.
Questions This Raises
- ?Can resistance exercise preserve lean mass during semaglutide treatment?
- ?Does the lean mass loss lead to functional impairment in older or frailer patients?
Trust & Context
- Key Stat:
- 115 patients, 12-month DXA data Prospective body composition tracking during semaglutide 2.4mg treatment
- Evidence Grade:
- Prospective observational study — provides objective body composition data but lacks a randomized control group.
- Study Age:
- Published 2026 in Diabetes, Obesity & Metabolism. Data from February 2022 to November 2024.
- Original Title:
- Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.
- Published In:
- Diabetes, obesity & metabolism, 28(1), 112-121 (2026)
- Authors:
- Alissou, Mathieu, Demangeat, Thomas, Folope, Vanessa, Van Elslande, Hélène, Lelandais, Hélène, Blanchemaison, Julia, Cailleaux, Pierre-Emmanuel, Guney, Suzan, Aupetit, Alexandra, Aubourg, Agnès, Rapp, Clément, Petit, André, Godin, Morgane, Vignal, Luc, Grigioni, Sébastien, Déchelotte, Pierre, Colange, Guillaume, Coëffier, Moïse, Achamrah, Najate
- Database ID:
- RPEP-14745
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide make you lose muscle along with fat?
Yes, this study found semaglutide causes some lean mass loss alongside fat loss, though muscle strength (measured by handgrip) was generally maintained through 12 months of treatment.
How was body composition measured in this study?
Researchers used DXA scans, considered the gold standard for measuring fat mass, lean mass, and bone density, at baseline, 7 months, and 12 months.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14745APA
Alissou, Mathieu; Demangeat, Thomas; Folope, Vanessa; Van Elslande, Hélène; Lelandais, Hélène; Blanchemaison, Julia; Cailleaux, Pierre-Emmanuel; Guney, Suzan; Aupetit, Alexandra; Aubourg, Agnès; Rapp, Clément; Petit, André; Godin, Morgane; Vignal, Luc; Grigioni, Sébastien; Déchelotte, Pierre; Colange, Guillaume; Coëffier, Moïse; Achamrah, Najate. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.. Diabetes, obesity & metabolism, 28(1), 112-121. https://doi.org/10.1111/dom.70141
MLA
Alissou, Mathieu, et al. "Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.." Diabetes, 2026. https://doi.org/10.1111/dom.70141
RethinkPeptides
RethinkPeptides Research Database. "Impact of Semaglutide on fat mass, lean mass and muscle func..." RPEP-14745. Retrieved from https://rethinkpeptides.com/research/alissou-2026-impact-of-semaglutide-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.